Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance
The DOI matches its Crossref record.
Abstract
Pancreatic and gut hormone responses to oral glucose, and insulin sensitivity were studied in cystic fibrosis patients with normal (N= 14), impaired (N=4), and diabetic (N= 12) glucose tolerance, and in 10 control subjects, and beta cell responses to oral glucose and intravenous glucagon were compared. Compared to control subjects, initial insulin and C-peptide responses to oral glucose were lower in all patient groups, and decreased with decreasing glucose tolerance. Insulin sensitivity in patients with impaired and diabetic glucose tolerance was lower than in control subjects. The 6 min post-glucagon C-peptide concentration was positively correlated with the initial insulin response to oral glucose. Fasting levels of pancreatic polypeptide, pancreatic glucagon, total glucagon, glucagon-like peptide-1 7-36 amide, and gastric inhibitory polypeptide were normal in all patient groups. Following oral glucose, pancreatic polypeptide responses were absent in all patients, suppressibility of pancreatic glucagon secretion was increasingly impaired with decreasing glucose tolerance, and gut hormone levels were normal. In conclusion, at cystic fibrosis (a) insulin secretion is impaired even when glucose tolerance and insulin sensitivity are within the normal range, (b) the glucagon test gives valid estimates of residual beta cell function, (c) pancreatic polypeptide response to oral glucose is absent, (d) glucagon suppressibility decreases with decreasing glucose tolerance, and (e) the enteroinsular axis is intact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diagnosis, screening and management of cystic fibrosis related diabetes mellitus
Moran, A., Hardin, D., Rodman, D., Allen, H. F., Beall, R. J., Borowitz, D., Brunzell, C., Campbell III, P. W., Chesrown, S. E., Duchow, C., et al. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00058-3 · Cited by 293
Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes
Moran, A., Becker, D., Casella, S. J., Gottlieb, P. A., Kirkman, M. S., Marshall, B. C., Slovis, B., & the CFRD Consensus Conference Committee (2010) · Diabetes Care · doi:10.2337/dc10-1279 · Cited by 258
Moran, A., Pillay, K., Becker, D., Granados, A., Hameed, S., & Acerini, C. L. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12732 · Cited by 171
Guo, J. H., Chen, H., Ruan, Y. C., Zhang, X. L., Zhang, X. H., Fok, K. L., Tsang, L. L., Yu, M. K., Huang, W. Q., Sun, X., et al. (2014) · Nature Communications · doi:10.1038/ncomms5420 · Cited by 157
CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells
Edlund, A., Pedersen, M. G., Lindqvist, A., Wierup, N., Flodström-Tullberg, M., & Eliasson, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-00098-8 · Cited by 63
Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis
Siwamogsatham, O., Alvarez, J. A., & Tangpricha, V. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000096 · Cited by 36
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T., Stecenko, A. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0380 · Cited by 35
Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis
Darukhanavala, A., Van Dessel, F., Ho, J., Hansen, M., Kremer, T., & Alfego, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250036 · Cited by 12
“Because of early loss of the first phase insulin response, the OGTT of CF patients without CFRD often reveals major abnormalities in early insulin secretion [1, 18, 19].”
Background
Metadata
- Authors
- Lanng, S., Thorsteinsson, B., Røder, M. E., Ørskov, C., Holst, J. J., Nerup, J., & Koch, C.
- Venue
- Acta Endocrinologica
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-03
- Volume
- 128
- Issue
- 3
- Pages
- 207-214
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2095195470
- Cited by
- 107
- References
- 0
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.